Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 9/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21048235 | 0.93 | CHRM4 (0.56) | CHRM4KDM4EMAPTKMT2AMAPK1 | |
| SCHEMBL21048226 | 0.84 | CHRM4 (0.59) | CHRM4KDM4EMAPTKMT2AMAPK1 | |
| SCHEMBL30187856 | 0.84 | CHRM4 (0.70) | CHRM4KDM4EMAPTKMT2A | |
| SCHEMBL19741115 | 0.84 | CHRM4 (0.70) | CHRM4KDM4EMAPTKMT2A | |
| Hydrochloric Acid SCHEMBL30193513 | 0.83 | CHRM4 (0.72) | CHRM4KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL19741177 | 0.83 | CHRM4 (0.72) | CHRM4KDM4EMAPT | |
| SCHEMBL21075921 | 0.82 | CHRM4 (0.48) | CHRM4 | |
| SCHEMBL21048214 | 0.82 | CHRM4 (0.69) | CHRM4KDM4EMAPTKMT2AMAPK1 | |
| SCHEMBL21048232 | 0.82 | CHRM4 (0.69) | CHRM4KDM4EMAPTKMT2AMAPK1 | |
| SCHEMBL21048259 | 0.79 | MAPK1 (0.71) | CHRM4KDM4EMAPTKMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3720860-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2020-10-14 | — | — | EP | claimed |
| US-10736898-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2020-08-11 | — | — | US | claimed |
| WO-2019113179-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2019-06-13 | — | — | WO | claimed |
| US-20190167688-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2019-06-06 | — | — | US | claimed |
| US-10736898-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-10736898-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190167688-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2019-06-06 | — | — | US | disclosed |
| US-20190167688-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736898-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM5, CHRM2 | CHRM4 1/4885KDM4E 862/4885MAPT 652/4885 |
| US-20190167688-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM5, CHRM2 | CHRM4 1/4885KDM4E 862/4885MAPT 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.